{"entity":{"id":"nct02659514","kind":"trial","name":"Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer","aka":[],"tldr":"A phase 2 trial of Poziotinib in Breast cancer, run by Spectrum Pharmaceuticals, Inc, completed.","summary":"Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer is a phase 2 interventional study registered as NCT02659514 by Spectrum Pharmaceuticals, Inc, with 67 participants recorded, started 2016-02-22 and reaching its primary completion in 2020-03-11. Interventions recorded: Poziotinib. Conditions recorded: Breast Cancer.\n\nLinked to the drug Poziotinib because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT02659514","url":"https://clinicaltrials.gov/study/NCT02659514"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["poziotinib"],"companies":["spectrum-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02659514","phase":"2","setting":"A Phase 2 Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens for MBC","sponsor":"Spectrum Pharmaceuticals, Inc","started":"2016-02-22","startedType":"actual","yearReported":2022,"enrolled":67,"enrolledBasis":"registry","outcomes":[{"endpoint":"Objective Response Rate (ORR)","primary":true,"unit":"%","arms":[{"name":"Cohort 1: Poziotinib 24 mg","n":30,"value":30,"note":"95% CI 14.7 to 49.4; Figures from the ClinicalTrials.gov results section (first posted 2022-02-10), not from a publication"},{"name":"Cohort 2: Poziotinib 16 mg","n":27,"value":30,"note":"95% CI 13.8 to 50.2"}],"source":"https://clinicaltrials.gov/study/NCT02659514?tab=results"},{"endpoint":"Progression Free Survival (PFS)","unit":"months","arms":[{"name":"Cohort 1: Poziotinib 24 mg","n":30,"value":4.1,"note":"95% CI 1.5 to 5.6; Figures from the ClinicalTrials.gov results section (first posted 2022-02-10), not from a publication"},{"name":"Cohort 2: Poziotinib 16 mg","n":27,"value":4.9,"note":"95% CI 1.8 to 7.4"}],"source":"https://clinicaltrials.gov/study/NCT02659514?tab=results"}]},"route":"/trials/nct02659514/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"poziotinib","kind":"drug","name":"Poziotinib","route":"/drugs/poziotinib/"}],"company":[{"id":"spectrum-pharmaceuticals","kind":"company","name":"Spectrum Pharmaceuticals","route":"/companies/spectrum-pharmaceuticals/"}]}}